TBC 3804

Drug Profile

TBC 3804

Latest Information Update: 24 Aug 2006

Price : $50

At a glance

  • Originator Encysive Pharmaceuticals
  • Class Anti-inflammatories
  • Mechanism of Action Alpha4-beta7 integrin antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammatory bowel diseases

Most Recent Events

  • 23 Aug 2006 Discontinued - Preclinical for Inflammatory bowel disease in USA (unspecified route)
  • 21 Dec 2004 Preclinical trials in Inflammatory bowel disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top